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Background: The majority of human papillomavirus (HPV)-negative squamous cell
carcinoma of the head and neck (SCCHN) present upregulation of the epidermal
growth factor receptor (EGFR) and frequent alterations in the cyclin D1-cyclin dependent
kinase (CDK) 4/6 (CDK 4/6)-retinoblastoma protein (pRb) pathway, resulting in cell
cycle progression and tumor proliferation. This study investigated the combination of
ribociclib, an orally highly selective inhibitor of CDK 4/6, and cetuximab in recurrent and/or
metastatic (R/M) SCCHN.
Methods: A phase I trial using a 3 + 3 design was performed to determine the dose
limiting toxicity (DLT) and maximum tolerated dose (MTD) of ribociclib with standard
dose of weekly cetuximab in HPV-negative patients with R/M SCCHN. Ribociclib was
administered orally (3 weeks on/1 week off) at dose level 1 of 400mg daily and dose level
2 of 600mg daily. The MTD of ribocilib was then further evaluated in an expansion cohort.
Results: 10 patients were enrolled in the escalation trial. No DLTs were observed at
dose level 1 (n = 3); at dose level 2, one patient was replaced due to rapid disease
progression, and one patient out of six evaluable patients experienced a DLT (grade
4 thrombocytopenia >7 days). Ribociclib 600mg daily was thus determined to be the
MTD. Eleven additional patients were enrolled in the expansion cohort. Diarrhea (52%),
rash (52%), fatigue (43%), nausea (33%), and mucositis (28%) were the most frequent
grade 1–2 adverse events (AE). Neutropenia was the most frequent grade 3–4 AE (20%).
Median progression-free survival (PFS) was 3.5 months (range 0.4–17.3 months) and
median overall survival (OS) was 8.3 months (range 0.4–24.1 months). Among the 19
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radiologically evaluable patients, two (10.5%) achieved a partial response and 11 (58%)
had stable disease.
Conclusions: The MTD of ribociclib is 600mg daily when administered in combination
with standard dose cetuximab for 3 weeks on and 1 week off. This combination was
safe and showed efficacy. Further clinical trials should be conducted to evaluate the
antitumor effects of this combination.
Trial Information:ClinicalTrials.gov: NCT02429089; Eudract number 2014-005371-83.
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INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) is a
major cause of cancer-associated illness and death worldwide,
with approximately 750,000 new cases diagnosed annually (1).
Most patients present with loco-regionally advanced disease
and are treated with multimodal treatment including surgery,
chemotherapy, and/or radiotherapy. However, 50% of patients
experience disease relapse with a median survival not exceeding
12–14 months (2).
The epidermal growth factor receptor (EGFR) is
overexpressed in 90% percent of SCCHN and is associated
with worse prognosis and resistance to radiotherapy (3, 4).
Cetuximab, a monoclonal antibody targeting the EGFR, has
been shown to improve outcome when combined with radiation
and chemotherapy (5, 6). In recurrent or metastatic (R/M)
SCCHN, the addition of cetuximab to first-line platinum-based
chemotherapy increases progression-free survival (PFS) from
3.3 to 5.6 months and overall survival (OS) from 7.4 to 10.1
months (6); however, resistance inexorably occurs. The efficacy
of cetuximab as monotherapy after failure of platinum-based
chemotherapy is modest at best as the overall response rate
(ORR) is only 13% and survival does not exceed 6 months
(7). This low response rate, together with treatment resistance
and the absence of correlation between EGFR expression and
cetuximab efficacy, suggest that additional factors, such as cell-
cycle regulation proteins, should be considered when targeting
the EGFR pathway (8).
CyclinD1 is encoded byCCND1 and is a cell-cycle protein that
regulates the G1-to-S phase transition through the formation of
complexes with cyclin dependent kinases (CDKs), such as CDK 4
and 6. Upon mitogenic signals, this complex cyclin D1-CDK4/6
inactivates by phosphorylation of the retinoblastoma protein
(pRb), a negative regulator of cell cycle progression. Inactivation
of pRb releases the transcription factor E2F, inducing expression
of the S-phase gene and stimulating cell proliferation. The cyclin
D1-CDK4/6 complex is inhibited by p16INK4A, which is encoded
by the gene CDKN2A (9, 10). SCCHN, and particularly HPV-
negative tumors, are characterized by frequent alterations in the
cyclin D1-CDK4/6-pRb pathway. In the Tumor Cancer Genome
Analysis (TCGA), CCND1 amplification was observed in 28%
of SCCHN, with its frequency reaching 32% in HPV-negative
tumors compared to only 6% in those that were HPV-positive.
Moreover, up to 57% of HPV-negative SCCHN have inactivation
of CDKN2A compared to 0% in HPV-positive tumors (11).
Overexpression of cyclin D1 and amplification of CCND1
in SCCHN are associated with poor prognosis and resistance
to cisplatin and EGFR inhibition (12, 13). Previously, EGFR
activity had been observed to regulate cell-cycle progression via
ERK1/2-dependent induction of CCND1 (14). Furthermore, a
recent study in HPV-negative patients showed a strong inverse
correlation between expression of EGFR and pRb inactivation
as well as between EGFR mRNA upregulation and CDK6
upregulation and amplification (15). Afatinib, or lapatinib
combined with a CDK4/6 inhibitor, is synergistic in terms of cell
viability reduction in HPV-negative cell lines (15).
Ribociclib is a selective CDK4/6 inhibitor which has
demonstrated antitumor activity in preclinical and clinical
studies in a wide variety of tumor types, including breast
cancer (16). We performed a phase I trial to determine the
maximum tolerated dose (MTD) of ribociclib combined with
standard weekly doses of cetuximab in patients with R/M HPV-
negative SCCHN.
MATERIALS AND METHODS
Inclusion and Exclusion Criteria
Eligible patients had to have R/M HPV-negative SCCHN
not amenable to curative treatment with surgery and/or
chemotherapy and/or radiation; progressive disease (PD) within
1 year of first-line platinum-based chemotherapy given either as
part of multimodal curative treatment or in the palliative setting;
Eastern Cooperative Oncology Group performance status
(ECOG PS) 0–1; at least one measurable lesion according to
the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST);
and the ability to swallow ribociclib tablets. Previous treatment
with cetuximab was allowed either in the metastatic or curative
setting (with radiation). Patients needed to have adequate
organ function, absolute neutrophil count (ANC) >1,500/mm3,
hemoglobin ≥9 g/dl, platelet count >100,000/mm3, serum
creatinine ≤1.5 the upper limit of normal (ULN), total bilirubin
≤1 ULN, and alanine aminotransferase (ALAT) and aspartate
aminotransferase (ASAT) <1.5 ULN. HPV-negative tumor was
defined by the absence of p16INK4A staining. The study was
approved by an independent ethics committee, the Belgian health
authorities, and conducted in accordance with the Declaration of
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Helsinki (October 2000).Written informed consent was obtained
for each patient.
Study Objectives
The primary objective was to determine the MTD of ribociclib
in combination with the recommended dose of cetuximab.
The secondary objective was to evaluate the toxicity profile
of ribociclib in combination with cetuximab in patients with
R/M SCCHN. With exploratory intent, we also assessed
treatment efficacy by reporting ORR [according to RECISTv1.1
(17)], PFS and OS. Tissue samples were collected for further
translational analysis.
Study Design
Cetuximab 400 mg/m2 was given intravenously on cycle 1
day 1, followed by 250 mg/m2 weekly, as per standard
recommendations (18). Ribociclib was administered orally with
food on days 1–21 of each 28-day cycle.
This phase I study used a classical 3 + 3 dose escalation
design. The first dose level of ribociclib was defined as 400mg/day
and the second dose level as 600 mg/day; three patients were
enrolled per dose level and intra-patient dose escalation was
not permitted. If zero out of three patients experienced a dose
limiting toxicity (DLT), the dose was escalated to the next dose
level. When one out of three patients experienced a DLT, three
additional patients had to be included. In the event that two
out of three or six patients experienced a DLT, dose escalation
had to be stopped. The MTD was defined as the dose below the
dose level at which two patients out of three or six experienced
DLTs. Given that the MTD of ribociclib monotherapy is 600mg,
it was not planned to escalate ribociclib above this dose (19).
In the event that the combination of ribociclib 600mg and
cetuximab (standard dosage) was found to be safe, it was pre-
planned that the MTD of ribociclib in combination would be
defined as 600 mg/day. DLTs and adverse events (AEs) were
determined according to the NCI-CTC version 4.0. DLTs were
evaluated during cycle 1 (4 weeks) and were defined as: (a)
grade 4 neutropenia lasting more than seven consecutive days,
(b) grade 4 thrombocytopenia, (c) grade 3–4 neutropenia with
fever, (d) any ribociclib-related grade 3–4 toxicities with the
exception of sub-optimally treated nausea/vomiting/diarrhea, or
brief (<72 h) grade three fatigue and grade three electrolyte
disturbance resolving to grade 1 with 7 days of drug interruption.
Criteria to initiate subsequent cycles included an ANC
≥1,000/mm3, platelets ≥50,000/mm3, and non-hematologic
toxicities ≤grade 1. If these were not met, ribociclib was delayed
for 1 week while cetuximab was continued. After a 2-week
delay, ribociclib was discontinued. The dose of ribociclib was
adjusted for selected AEs. A dose decrease by 200 mg/day was
recommended for grade 4 neutropenia/thrombocytopenia, grade
3 neutropenia with infection/fever, grade ≥3 non-hematologic
toxicity, or treatment delay >1 week due to persisting AE if
recovery occurred within 2 weeks. At 400mg, one dose reduction
was allowed, while at 600mg, two dose reductions were allowed.
Patients who required more than two dose reductions were
treated with cetuximab alone.
After identification of the MTD, 14 patients were initially
planned to be enrolled in an expansion cohort to further confirm
the safety of this combination.
Treatment emergent adverse events (TEAE) were defined as
events that occurred after study treatment initiation, or those that
worsened relative to the pre-treatment state.
Tumor Response Assessment
The efficacy of the ribociclib-cetuximab combination was
evaluated with exploratory intent. Tumor response assessment
was performed every two cycles (8 weeks), according to RECIST
v1.1 criteria. ORR was defined as the proportion of patients with
a complete response (CR) or a partial response (PR). PFS was
defined as the time interval between the date of enrolment and
the date of disease progression or the date of death due to any
cause. OS was defined as the time interval between the date of
enrolment until death due to any cause, or until the date of last
follow-up. Patients with unknown or missing response data were
treated as non-responders.
Statistical Methods
The number of patients for dose escalation was determined by
the MTD and DLTs to a maximum of 12 patients. Expecting
an ORR >20% with the combination, 14 patients were planned
to be included in the expansion phase with a 95.6% chance of
achieving at least one success. PFS and OS were also estimated
according to the Kaplan-Meier algorithm. Patients without any




Twenty-one patients (14 men and 7 women) from five Belgian
centers were included between April 2015 and May 2017 in this
trial. Ten patients were included in the escalation cohort and,
due to slow recruitment and premature closure of the study, only
11 were enrolled in the expansion cohort. The median age was
61.1 years (range 33–80 years). Fourteen patients (67%) were
previously treated with cetuximab. Baseline characteristics are
described in Table 1.
Dose Limiting Toxicity and Maximum
Tolerated Dose
Three patients were enrolled in dose level 1 (400 mg/day)
of ribociclib and no DLT was observed. Seven patients were
enrolled in the dose level 2 escalation phase (600 mg/day):
one patient presented with rapid disease progression (within
7 days) and was replaced as he could not be evaluated for
DLT assessment; another experienced a DLT with grade 4
thrombocytopenia. Ribociclib 600mg daily for 3 weeks on and 1
week off with standard dose cetuximab was therefore considered
to be the MTD.
Safety
Table 2 shows the most frequent TEAEs that occurred in the 21
patients regardless of dose levels. Diarrhea (52%), rash (52%),
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TABLE 1 | Patient characteristics.
Baseline characteristics Ribociclib + Cetuximab
(N = 21)
Age (Years)








>10 pack-year 19 (91%)
<10 pack-year 2 (9%)
Primary Site
Oropharynx 4 (19%)
Oral cavity 9 (43%)
Hypopharynx 3 (14%)
Larynx 2 (10%)
Unknown primary 3 (14%)
Tumor Grade At Diagnosis
Well-differentiated 6 (29%)
Moderately differentiated 9 (43%)
Poorly differentiated 3 (14%)
Unknown/missing 3 (14%)
Location Of Relapse At Inclusion
Local and/or regional only 14 (67%)
Metastatic alone 3 (14%)
Loco-regional and metastatic 4 (19%)
Primary Curative Treatment
Surgery 16 (76%)
Radiation therapy 19 (90.5%)
Chemotherapy
Induction 0 (0%)












2 or more 7 (33%)
Previous Cetuximab Administration
Curative intent 10 (48%)
Recurrent/metastatic setting 4 (19%)
fatigue (43%), nausea (33%), and mucositis (28%) were the most
frequent grade 1–2 AEs. Neutropenia was the most frequent
grade 3–4 AE (20%). No febrile neutropenia was observed, and
no grade 5 toxicity was recorded.





Cetuximab (n = 21)
Grade 1–2 Grade 3–4
Number of patients with any
TEAEs
20 (95%) 9 (43%)
Constitutional
Fatigue 9 (43%) 1 (4%)
Anorexia 3 (14%) 2 (9%)
Rash 11 (52%) 0 (0%)
Pruritis 3 (14%) 0 (0%)
Conjunctivitis 2 (9%) 0 (0%)
Headache 2 (9%) 0 (0%)
QTc interval prolongation 1 (4%) 0 (0%)
GASTROINTESTINAL
Nausea 7 (33%) 0 (0%)
Vomiting 5 (24%) 0 (0%)
Diarrhea 11 (52%) 0 (0%)
Oral mucositis 6 (28%) 1 (4%)
Dysphagia 2 (9%) 0 (0%)
Heartburn 1 (4%) 0 (0%)
HEMATOLOGICAL
Anemia 5 (24%) 1 (4%)
Thrombocytopenia 6 (28%) 3 (14%)
Neutropenia 6 (28%) 4 (20%)
Lymphopenia 0 (0%) 3 (14%)
BIOLOGICAL
Hypomagnesemia 7 (33%) 1 (4%)
Hypocalcemia 3 (14%) 1 (4%)
Hypokalemia 2 (9%) 1 (4%)
Hypophosphatemia 4 (20%) 0 (0%)
The median number of administered cycles was two (range
2–4) in patients receiving ribociclib 400mg (n = 3), and three
(range 0–19) in patients receiving ribociclib 600mg (n= 18). One
patient stopped ribociclib treatment 3 days after initiation due
to rapid disease progression; two patients interrupted ribociclib
temporarily and restarted with the same dose (one interrupted
treatment for 14 days due to grade 3 anemia, while the other
interrupted for seven days due to QT interval increase at 481ms
occurring without concomitant use of medication with a known
risk to prolong the QT interval); five patients had a dose
reduction (one for grade 3 fatigue and thrombocytopenia, one
for grade 3 thrombocytopenia and neutropenia, and three for
grade 3 neutropenia). Eighteen patients stopped due to disease
progression, one died during treatment due to septic shock not
related to ribociclib, one decided to stop despite stable disease
(SD), and one stopped after a long lasting remission.
Efficacy
Median PFSwas 3.5months (range 0.4–17.3months) andmedian
OS was 8.3 months (0.4–24.1 months). The PFS rates at six and
12-months were 19 and 4.7%, and the corresponding OS rates
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FIGURE 1 | Waterfall plots showing the maximum percentage modification in
the sum of the diameters of the target lesions in assessable patients.
were 71 and 33%, respectively. Four patients remained alive after
a median follow-up of 9.2 months (range 0.25–39 months). PFS
was similar between patients previously treated and untreated
with cetuximab (100 and 106 days, respectively).
Two patients were not evaluable for radiological evaluation;
one patient progressed rapidly within 7 days of treatment
initiation, and one died from septic shock not related to
medication before the first radiological evaluation. Among the
19 evaluable patients, two (10.5%) achieved a PR, 11 (58%) had
SD, and six (36%) had PD, resulting in a disease control rate
(SD + PR) of 68.5%. Two of the 11 SD patients experienced a
minor response with a maximum reduction in the sum of the
diameters of the target lesions of −24 and −16% (Figure 1).
From the 14 patients previously treated with cetuximab (10
with curative-intent and 4 in R/M setting), 10 presented with
disease stabilization (including one with minimal reduction of
the target lesion) and one experienced a partial response. This
last patient was treated in a curative setting with cetuximab and
the interval between last dose of cetuximab and study entry
was 6 months. The four patients previously treated in R/M
setting curative-intent presented a SD (without minor reduction
of target lesions).
DISCUSSION
This trial is the first to establish the feasibility of combining
the selective CDK4/6 inhibitor ribociclib with cetuximab
in HPV-negative SCCHN. The escalation phase of this
study identified 600mg daily for 3 weeks on followed
by 1 week off as the MTD of ribociclib in combination
with cetuximab, which is also the recommended dose
in metastatic breast cancer in association endocrine
therapy (16).
The AEs observed in this trial were as expected for each
drug, and the toxicity profile was consistent with a phase
I trial that evaluated the association of palbociclib and
cetuximab in SCCHN (20). Myelosupression was the main
grade 3–4 AE related to ribociclib, manifesting principally
as thrombocytopenia and neutropenia that resulted in
dose reduction but not in definitive arrest. Gastrointestinal
AEs were mostly mild and easily manageable. Fatigue and
anorexia may have been related to ribociclib but are also
frequently observed in heavily pretreated patients with advanced
stage SCCHN.
We had to stop the trial early due to low accrual given
that most of the investigators were opting to include their
suitable patients in trials investigating anti-PD1 inhibitors.
Although this trial was limited by small patient numbers, the
combination of ribociclib and cetuximab resulted in an ORR
of 10%, a disease control rate of 68%, a PFS of 3.5 months
and an OS of 8.3 months. Interestingly, two patients pre-treated
with cetuximab experienced some degree of tumor shrinkage.
Recently, a phase II trial evaluated the efficacy of palbociclib
combined with cetuximab in patients with platinum-resistant
R/M SCCHN and reported a CR of 11% and PR of 29% for
an ORR of 39%; median PFS reached 5.4 months and the
median OS was 9.5 months (21). These results are promising
and exceed, at least in terms of survival, those observed with
nivolumab in the CheckMate 141 trial (22). However, this
last study excluded patients previously treated with cetuximab
for R/M setting and only 7% of the included patients had
received cetuximab in a curative setting, which could explain
the better results they observed compared to our trial (21).
Indeed, our population included around 70% of patients who
had previously been treated with cetuximab and this may have
impaired treatment activity.
This phase I trial is the first to evaluate the combination
of ribociclib and cetuximab in HPV-negative SCCHN.
The recommended dose is 600mg daily on a 3-weeks on
and 1-week off schedule in combination with cetuximab
at its standard dose. This combination proved safe. A
larger phase II trial should be conducted in HPV-negative
SCCHN patients to correctly evaluate the antitumor efficacy of
this combination.
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